- Home
- COLL vs NVRI Comparison
COLL vs NVRI Comparison
Compare COLL & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | NVRI |
|---|---|---|
| Founded | 2002 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | NVRI |
|---|---|---|
| Price | $45.38 | $18.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.17 | N/A |
| AVG Volume (30 Days) | 512.5K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | $757,067,000.00 | ★ $2,244,061,000.00 |
| Revenue This Year | $26.17 | N/A |
| Revenue Next Year | $3.65 | $3.42 |
| P/E Ratio | $28.19 | ★ N/A |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $4.72 |
| 52 Week High | $50.79 | $19.32 |
Technical Indicators
Market Signals| Indicator | COLL | NVRI |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 63.28 |
| Support Level | $44.43 | $18.09 |
| Resistance Level | $48.29 | $19.01 |
| Average True Range (ATR) | 2.15 | 0.32 |
| MACD | -0.25 | -0.04 |
| Stochastic Oscillator | 31.27 | 59.29 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.